Showing results (231-240 of 294) with videos related to
Sort By:
Pageof 30
Alcoholism, Clinical and Experimental Research|May 1, 2008
No role of matrixmetalloproteinase-3 genetic promoter polymorphism 1171 as a risk factor for cirrhosis in alcoholic liver diseaseFelix Stickel, Christoph H Osterreicher, Juliane Halangk, et al.Hepatology (Baltimore, Md.)|July 5, 2019
Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR TrialsQuentin M Anstee, Eric J Lawitz, Naim Alkhouri, et al.Scientific Reports|July 5, 2017
MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individualsBenedetta Donati, Paola Dongiovanni, Stefano Romeo, et al.Liver Cancer|January 2, 2023
Sulfatase-2 from Cancer Associated Fibroblasts: An Environmental Target for Hepatocellular Carcinoma?Marco Y W Zaki, Sari F Alhasan, Ruchi Shukla, et al.Journal of Hepatology|November 28, 2020
Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scoresCristiana Bianco, Oveis Jamialahmadi, Serena Pelusi, et al.Cancer Medicine|July 6, 2017
Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver diseaseBenedetta Donati, Alessandro Pietrelli, Piero Pingitore, et al.Hepatology (Baltimore, Md.)|July 28, 2023
Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)Mazen Noureddin, Emily Truong, Rebeca Mayo, et al.Journal of Hepatology|December 13, 2021
The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?Jeffrey V Lazarus, Henry E Mark, Marcela Villota-Rivas, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 18, 2014
Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitisVlad Ratziu, Pierre Bedossa, Sven M Francque, et al.The New England Journal of Medicine|October 20, 2021
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASHSven M Francque, Pierre Bedossa, Vlad Ratziu, et al.Pageof 30